Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06095102 · ClinicalTrials.gov registry record · Phase 3
A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)
A Phase 3 study of Plaque Psoriasis, sponsored by Janssen Research & Development.
- Active
- Registry status
- Phase 3
- Development phase
- 311
- Enrollment target
- 20
- Study locations
NCT06095102 is a Phase 3 study of Plaque Psoriasis that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 311 participants, below the 409-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (24% lower). The trial reports 20 study locations across 17 states.
The verdict
NCT06095102, a Phase 3 study of Plaque Psoriasis, is active but no longer recruiting, sponsored by Janssen Research & Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 311 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to see how effective JNJ-77242113 is in participants with plaque psoriasis affecting special areas (scalp, genital, and/or palms of the hands and the soles of the feet).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG JNJ-77242113
Study Locations (20)
Illinois
- Arlington Dermatology - Rolling Meadows
- Dundee Dermatology - West Dundee
Indiana
- Dawes Fretzin Clinical Research Group LLC - Indianapolis
- Indiana Clinical Trial Center - Plainfield
Pennsylvania
- Paddington Testing Co, Inc. - Philadelphia
- University of Pittsburgh Medical Center - Pittsburgh
Arizona
- Center for Dermatology and Plastic Surgery - Scottsdale
Arkansas
- Johnson Dermatology - Fort Smith
California
- California Dermatology & Clinical Research Institute - Encinitas
Florida
- Forcare Clinical Research Inc - Tampa
Georgia
- Hamilton Research LLC - Alpharetta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 311 participants |
| Start Date | 2023-10-12 |
| Est. Completion | 2027-02-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06095102
The ClinicalTrials.gov registry entry for NCT06095102 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 311 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 409-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (24% lower). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Plaque Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06095102 reports 20 study locations spanning 17 distinct geographic areas - top geographies include Illinois, Indiana, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06095102 about?
NCT06095102 is a clinical study titled "A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)". The purpose of the study is to see how effective JNJ-77242113 is in participants with plaque psoriasis affecting special areas (scalp, genital, and/or palms of the hands and the soles of the feet).
What is the current status of trial NCT06095102?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 311 participants. The study started on 2023-10-12. Estimated completion is 2027-02-17.
What conditions does trial NCT06095102 study?
This clinical trial studies the following conditions: Plaque Psoriasis.
What interventions are being tested in trial NCT06095102?
The interventions under investigation include: Placebo (DRUG), JNJ-77242113 (DRUG).
Who is sponsoring clinical trial NCT06095102?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06095102 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plaque Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
RECRUITING · Phase 3
-
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
RECRUITING · Phase 3
-
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
ACTIVE NOT RECRUITING · Phase 3
-
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.